Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accent Microcell's revenue for the
six
months ended in Mar. 2026 was ₹3,490 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₹3,490 Mil.
Accent Microcell's Revenue per Share for the
six
months ended in Mar. 2026 was ₹148.42.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹148.42.
During the past 12 months, the average Revenue per Share Growth Rate of Accent Microcell was 24.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 18.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 20.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 6 years, Accent Microcell's highest 3-Year average Revenue per Share Growth Rate was 34.10% per year. The lowest was 17.00% per year. And the median was 18.70% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Accent Microcell Revenue Related Terms
Accent Microcell Revenue Historical Data
* Premium members only.
The historical data trend for Accent Microcell's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Accent Microcell's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accent Microcell Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accent Microcell's Revenue distribution charts can be found below:
* The bar in red indicates where Accent Microcell's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₹3,490 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accent Microcell (NSE:ACCENTMIC) has a Revenue of ₹3,490 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Accent Microcell and its competitors.
Is Accent Microcell's Revenue too high?
Accent Microcell's current Revenue is ₹3,490 Mil. Overall, Accent Microcell has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Accent Microcell's Revenue compare to ZTS?
Accent Microcell's Revenue of ₹3,490 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Accent Microcell and its competitors. Accent Microcell's current Revenue is ₹3,490 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accent Microcell stock overvalued right now?
Accent Microcell (NSE:ACCENTMIC) has a current Revenue of ₹3,490 Mil. The current Revenue is ₹3,490 Mil. Accent Microcell's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Accent Microcell (NSE:ACCENTMIC), the current Revenue is ₹3,490 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accent Microcell Ltd is engaged in the manufacturing business of pharmaceutical excipients including products like Microcrystalline Cellulose which is a term for refined wood pulp and is used as a texturizer, an anti-caking agent, a fat substitute, an emulsifier, an extender, and a bulking agent in food production; Croscarmellose Sodium used as a super disintegrant in pharmaceutical formulations; Magnesium Stearate; Cellulose Powder, and others. Its business segments are segregated based on the location of its manufacturing facilities and include Dahej (SEZ Unit), Pirana, Unit III, and Inter Unit Sales. Geographically, a majority of the company's revenue is derived through the export of its products to various countries.
49GF Score
Get the complete analysis for NSE:ACCENTMIC
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ACCENTMIC has been successfully added to your 
